Aethlon Medical (NASDAQ:AEMD) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report sent to investors on Saturday. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Aethlon Medical in a report on Friday.

Aethlon Medical Stock Performance

Shares of AEMD opened at $0.40 on Friday. Aethlon Medical has a 1 year low of $0.24 and a 1 year high of $2.35. The stock has a market capitalization of $5.58 million, a PE ratio of -0.14 and a beta of 1.74. The stock has a 50-day simple moving average of $0.40 and a 200-day simple moving average of $0.48.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.10. During the same quarter in the previous year, the company posted ($1.30) earnings per share. Analysts predict that Aethlon Medical will post -1.1 EPS for the current year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.